Search for an orphan drug
Other search option(s)
Marketing authorization without orphan designation - Europe
- Tradename: CEPROTIN
- ATC code : B01AD12
- EU Number: EU/1/01/190/...
- MA date : 16/07/2001
- MA holder: BAXTER AG
- European Public Assessment Report
Therapeutic indication
Ceprotin is indicated in purpura fulminans and coumarin-induced skin necrosis in patients with severe congenital protein C deficiency.
Furthermore Ceprotin is indicated for short-term prophylaxis in patients with severe congenital protein C deficiency if one or more of the following conditions are met:
- surgery or invasive therapy is imminent,
- while initiating coumarin therapy,
- when coumarin therapy alone is not sufficient,
- when coumarin therapy is not feasible.
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.